Biogen Q2 2026 Earnings Overview

Biogen announced second‑quarter 2026 results that exceeded analyst expectations on both revenue and adjusted earnings per share (EPS). Revenue increased 3% year‑on‑year to $2.74 billion, beating the Bloomberg consensus estimate of $2.47 billion. Product revenue grew 2% to $1.92 billion, also topping the consensus forecast of $1.77 billion.

Adjusted EPS declined to $3.60 from $5.47 a year earlier but still outperformed the consensus estimate of $2.89. The company highlighted that its Growth Portfolio generated $1.06 billion in revenue, representing a 24% year‑on‑year increase and surpassing the legacy multiple‑sclerosis business in revenue contribution during the quarter.

Among individual products, global in‑market sales of the Alzheimer’s therapy Leqembi rose 15% to $184 million, falling short of the $186.4 million analyst estimate. U.S. in‑market sales of Leqembi reached $97 million, showing sequential growth, and the U.S. Food and Drug Administration approved Leqembi IQLIK for at‑home initiation in the quarter.

Spinraza revenue increased 2% to $402 million, driven by demand and stocking for the high‑dose regimen, though partially offset by shipment timing issues in certain international markets. Slyclarys revenue rose 29% to $168 million, primarily on higher global demand, while Zurzuvae sales climbed 53% to $71 million on demand growth. Conversely, Vumerity revenue fell 7% to $197 million, mainly due to inventory dynamics.

Biogen updated its 2026 outlook, raising the underlying non‑GAAP diluted EPS guidance to a range of $15.85‑$16.85 from the prior $15.25‑$16.25. The reported non‑GAAP diluted EPS guidance was revised to $12‑$13 to reflect acquisition‑related items and milestones. The company also projected full‑year revenue to increase by a mid‑single‑digit percentage versus 2025.

Additional commentary noted that analysts had previously expected a 7.8% year‑on‑year revenue decline for the quarter, a reversal from a 7.3% increase in the same quarter the prior year, but Biogen’s actual performance contradicted that expectation. Analysts have reconfirmed their estimates over the past 30 days, and the firm’s history of exceeding Wall Street expectations was reiterated.